Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
作者信息
Day J M, Houston J B
出版信息
Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x.
Abstract
摘要
相似文献
1
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.唾液：对正常志愿者和炎症性肠病患者给予柳氮磺胺吡啶后磺胺吡啶的唾液与血浆浓度关系。
Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x.
2
Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
Eur J Clin Pharmacol. 1984;26(2):275-7. doi: 10.1007/BF00630300.
3
Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.溃疡性结肠炎和克罗恩病患者中磺胺吡啶的乙酰化多态性
Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):514-20. doi: 10.1002/cpt1975185part1514.
4
Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Clin Pharmacol Ther. 1977 Dec;22(6):917-27. doi: 10.1002/cpt1977226917.
5
Sulphasalazine treatment during breast feeding.
Scand J Gastroenterol. 1979;14(7):869-71. doi: 10.3109/00365527909181418.
6
The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.利福平对柳氮磺胺吡啶给药后磺胺吡啶血浆浓度的影响。
Br J Clin Pharmacol. 1985 Apr;19(4):526-8. doi: 10.1111/j.1365-2125.1985.tb02682.x.
7
Azo reduction of sulphasalazine in healthy volunteers.
Br J Clin Pharmacol. 1982 Sep;14(3):395-8. doi: 10.1111/j.1365-2125.1982.tb01997.x.
8
Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites.
Scand J Gastroenterol. 1981;16(5):693-7. doi: 10.3109/00365528109182032.
9
Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.柳氮磺胺吡啶在类风湿关节炎和炎性肠病中的单剂量药代动力学比较。
Ann Rheum Dis. 1990 Aug;49(8):587-90. doi: 10.1136/ard.49.8.587.
10
Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.来自市售肠溶包衣和未包衣柳氮磺吡啶片剂的磺胺吡啶的相对全身可用性。
J Clin Pharmacol. 1979 Jan;19(1):39-45. doi: 10.1002/j.1552-4604.1979.tb01615.x.
引用本文的文献
1
Azo reduction of sulphasalazine in healthy volunteers.
Br J Clin Pharmacol. 1982 Sep;14(3):395-8. doi: 10.1111/j.1365-2125.1982.tb01997.x.
2
Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
Eur J Clin Pharmacol. 1981;21(3):243-50. doi: 10.1007/BF00627927.
本文引用的文献
1
THE BINDING OF SULFONAMIDE DRUGS BY PLASMA PROTEINS. A FACTOR IN DETERMINING THE DISTRIBUTION OF DRUGS IN THE BODY.血浆蛋白与磺胺类药物的结合：决定药物在体内分布的一个因素
J Clin Invest. 1943 Sep;22(5):753-62. doi: 10.1172/JCI101448.
2
Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.柳氮磺胺吡啶给药后生物材料中磺胺吡啶及其代谢产物的测定
Acta Pharm Suec. 1973 Mar;10(1):87-92.
3
Active therapeutic moiety of sulphasalazine.
Lancet. 1978 Feb 4;1(8058):277. doi: 10.1016/s0140-6736(78)90524-x.
4
An experiment to determine the active therapeutic moiety of sulphasalazine.一项确定柳氮磺胺吡啶活性治疗部分的实验。
Lancet. 1977 Oct 29;2(8044):892-5. doi: 10.1016/s0140-6736(77)90831-5.
5
High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.
J Chromatogr. 1979 Feb 21;162(2):237-43. doi: 10.1016/s0378-4347(00)81919-2.
6
Therapeutic drug monitoring in saliva.唾液中的治疗药物监测。
Clin Pharmacokinet. 1978 Jan-Feb;3(1):39-57. doi: 10.2165/00003088-197803010-00003.
7
Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
Clin Pharmacol Ther. 1977 Dec;22(6):917-27. doi: 10.1002/cpt1977226917.
8
Clinical pharmacokinetics of sulphasalazine.柳氮磺胺吡啶的临床药代动力学
Clin Pharmacokinet. 1976 Nov-Dec;1(6):406-25. doi: 10.2165/00003088-197601060-00002.
Zotero 插件